Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates

分组1 - Aurinia Pharmaceuticals reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to a loss of $0.09 per share a year ago, representing an earnings surprise of 400% [1] - The company posted revenues of $67.77 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 14.74%, and compared to year-ago revenues of $54.52 million [2] - Aurinia has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times in the same period [2] 分组2 - The stock has underperformed the market, losing about 16.4% since the beginning of the year, while the S&P 500 gained 24.3% [3] - The current consensus EPS estimate for the coming quarter is $0.11 on revenues of $68.33 million, and for the current fiscal year, it is $0.04 on revenues of $235.59 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 33% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]